Go Pro
→ Elon Musk’s One Stock Retirement Plan (From Brownstone Research) (Ad)tc pixel Free BCLI Stock Alerts

Brainstorm Cell Therapeutics (BCLI) Competitors

Brainstorm Cell Therapeutics logo
$0.90 -0.08 (-8.16%)
As of 09/18/2026 03:42 PM Eastern
Compare

BCLI vs. MCRB, HOWL, MGX, MREO, and CELU

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? Brainstorm Cell Therapeutics's main competitors and comparable companies include Seres Therapeutics (MCRB), Werewolf Therapeutics (HOWL), Metagenomi (MGX), Mereo BioPharma Group (MREO), and Celularity (CELU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Brainstorm Cell Therapeutics compare to Seres Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Brainstorm Cell TherapeuticsN/A N/A -519.50%
Seres Therapeutics -1,192.94%-114.82%-34.15%

In the previous week, Seres Therapeutics' average media sentiment score of 1.87 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Brainstorm Cell Therapeutics Neutral
Seres Therapeutics Very Positive

Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 325.00%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Seres Therapeutics has higher revenue and earnings than Brainstorm Cell Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A
Seres Therapeutics$790K50.89$5.70M-$2.43N/A

Brainstorm Cell Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics beats Brainstorm Cell Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Werewolf Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Brainstorm Cell Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Brainstorm Cell TherapeuticsN/A N/A -519.50%
Werewolf Therapeutics N/A -166.99%-59.88%

In the previous week, Werewolf Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 1 mentions for Werewolf Therapeutics and 0 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company Overall Sentiment
Brainstorm Cell Therapeutics Neutral
Werewolf Therapeutics Neutral

Werewolf Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 314.51%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A
Werewolf Therapeutics$1.88M24.95-$60.82M-$0.76N/A

Summary

Werewolf Therapeutics beats Brainstorm Cell Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Metagenomi presently has a consensus price target of $6.00, suggesting a potential upside of 445.45%. Given Metagenomi's stronger consensus rating and higher possible upside, equities analysts plainly believe Metagenomi is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Metagenomi. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metagenomi$25.21M1.65-$87.87M-$2.49N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Metagenomi's average media sentiment score of 1.92 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Metagenomi is being referred to more favorably in the media.

Company Overall Sentiment
Metagenomi Very Positive
Brainstorm Cell Therapeutics Neutral

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
Metagenomi-384.61% -63.65% -44.52%
Brainstorm Cell Therapeutics N/A N/A -519.50%

Metagenomi has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Summary

Metagenomi beats Brainstorm Cell Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma GroupN/A -74.82% -64.28%
Brainstorm Cell Therapeutics N/A N/A -519.50%

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mereo BioPharma Group has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Mereo BioPharma Group presently has a consensus target price of $1.67, indicating a potential upside of 450.06%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, research analysts clearly believe Mereo BioPharma Group is more favorable than Brainstorm Cell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mereo BioPharma Group
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group$500K96.77-$41.88M-$0.04N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 1 mentions for Mereo BioPharma Group and 0 mentions for Brainstorm Cell Therapeutics. Mereo BioPharma Group's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group Neutral
Brainstorm Cell Therapeutics Neutral

Summary

Mereo BioPharma Group beats Brainstorm Cell Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Celularity?

Celularity (NASDAQ:CELU) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

19.0% of Celularity shares are held by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Brainstorm Cell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Celularity had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 1 mentions for Celularity and 0 mentions for Brainstorm Cell Therapeutics. Celularity's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company Overall Sentiment
Celularity Neutral
Brainstorm Cell Therapeutics Neutral

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Celularity. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$26.55M1.43-$91.72M-$3.33N/A
Brainstorm Cell TherapeuticsN/AN/A-$11.62M-$1.65N/A

Celularity has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -345.45%.

Company Net Margins Return on Equity Return on Assets
Celularity-345.45% N/A -77.94%
Brainstorm Cell Therapeutics N/A N/A -519.50%

Summary

Celularity beats Brainstorm Cell Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCLI vs. The Competition

Export
MetricBrainstorm Cell TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.97M$3.89B$7.25B$12.95B
Dividend YieldN/A3.64%2.57%12.80%
P/E Ratio-0.278.10210.2920.60
Price / SalesN/A1,456.59656.3793.45
Price / CashN/A41.6228.1334.74
Price / Book-0.6615.4710.506.32
Net Income-$11.62M-$22.90M$3.49B$358.20M
7 Day Performance-16.67%-1.21%0.59%1.12%
1 Month Performance-15.09%-3.29%-1.74%-2.39%
1 Year Performance28.66%37.74%18.13%5.35%

Brainstorm Cell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCLI
Brainstorm Cell Therapeutics
N/A$0.90
-8.2%		N/A+28.7%$13.97MN/AN/A40
MCRB
Seres Therapeutics
3.5453 of 5 stars		$4.60
-2.7%		$17.00
+269.6%		-77.1%$47.51M$790KN/A330
HOWL
Werewolf Therapeutics
2.424 of 5 stars		$0.98
+2.3%		$4.00
+308.2%		-35.2%$46.55M$1.88MN/A40
MGX
Metagenomi
4.0859 of 5 stars		$1.16
-2.5%		$6.00
+417.2%		-46.3%$44.96M$25.21MN/A236
MREO
Mereo BioPharma Group
3 of 5 stars		$0.29
+1.8%		$1.67
+484.8%		-82.6%$44.71M$500KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
The Last Gold Bull Market?
Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...
Paradigm Press | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
No Wallstreet. No Advisor. No Problem.
Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...
Awesomely | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel